AI Article Synopsis
- Glioblastoma (GBM) is a challenging cancer due to its aggressive behavior and resistance to standard treatments, particularly immunotherapy.
- A new Sequential Release HydroLipo System (SRHLS) has been developed, combining hydrogels and nanoparticles to enable controlled drug release that allows for the sequential administration of decitabine and STING agonists.
- This innovative system has been shown to improve tumor microenvironment, significantly inhibiting tumor growth, recurrence, and metastasis, highlighting its potential as an effective treatment for GBM.
Article Abstract
Glioblastoma (GBM) remains a daunting oncological challenge because of its aggressive nature and resistance to conventional therapies. Inhibition of the intrinsic STING pathway in GBM hampers the effectiveness of immunotherapies. To overcome this clinical limitation, a Sequential Release HydroLipo System (SRHLS) is developed, in which hydrogels and nanoparticles are combined for controlled drug release. The SRHLS sequentially released decitabine and STING agonists, thereby correcting STING signaling dysfunction through epigenetic reprogramming and enhancing antitumor immunity. According to in vitro and in vivo experiments, the SRHLS reshaped the tumor microenvironment and markedly inhibited tumor growth, recurrence, and metastasis. These findings underscore the potential of the SRHLS as a promising therapeutic strategy for GBM.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/advs.202408323 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sequential Targeting Chondroitin Sulfate-Bilirubin Nanomedicine Attenuates Osteoarthritis via Reprogramming Lipid Metabolism in M1 Macrophages.
Adv Sci (Weinh)
January 2025
Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
The infiltration and excessive polarization of M1 macrophages contribute to the induction and persistence of low-grade inflammation in joint-related degenerative diseases such as osteoarthritis (OA). The lipid metabolism dysregulation promotes M1 macrophage polarization by coordinating the compensatory pathways of the inflammatory and oxidative stress responses. Here, a self-assembling, licofelone-loaded nanoparticle (termed LCF-CSBN), comprising chondroitin sulfate and bilirubin joined by an ethylenediamine linker, is developed to selectively reprogram lipid metabolism in macrophage activation.
View Article and Find Full Text PDFConvertible Hydrogel Injection Sequentially Regulates Diabetic Periodontitis.
ACS Biomater Sci Eng
January 2025
Chongqing Key Laboratory of Reproductive Health and Digital Medicine, Department of Laboratory Medicine, Chongqing General Hospital, School of Medicine, Chongqing University, Chongqing 401147, China.
Diabetes exacerbates periodontitis by overexpressing reactive oxygen species (ROS), which leads to periodontal bone resorption. Consequently, it is imperative to relieve inflammation and promote alveolar bone regeneration comprehensively for the development of diabetic periodontal treatment strategies. Furthermore, an orderly treatment to avoid interference between these two processes can achieve the optimal therapeutic effect.
View Article and Find Full Text PDFGeochemical partitioning and leaching behaviour of geogenic contaminants from the partially weathered rocks in chronic kidney disease of unknown etiology (CKDu) endemic regions in Sri Lanka.
Environ Geochem Health
January 2025
Ecosphere Resilience Research Centre, Faculty of Applied Sciences, University of Sri Jayewardenepura, Nugegoda, 10250, Sri Lanka.
Studies regarding geochemical partitioning and leaching behavior of Hofmeister ions, which is considered as a risk/causative factor for chronic kidney disease of unknown etiology (CKDu), are scarce. Therefore, Hofmeister ions' leaching behavior of partially weathered rocks from CKDu endemic (Girandurukotte) and non-endemic (Sewanagala) areas, Sri Lanka were compared. Rock mineralogy was analyzed using X-ray Diffraction, and total ion contents were determined using alkaline and acid digestions.
View Article and Find Full Text PDFTransformation of lung adenocarcinoma to small cell lung cancer following osimertinib treatment: a case report and literature review.
Anticancer Drugs
January 2025
Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) effectively treat EGFR-mutant lung adenocarcinoma, demonstrating initial efficacy but eventually leading to acquired resistance. Small cell transformation is a rare resistance mechanism to EGFR-TKIs in lung adenocarcinoma, which can complicate clinical diagnosis and treatment. We present a patient with lung adenocarcinoma who underwent a prior pneumonectomy and adjuvant chemotherapy and was treated with osimertinib after the recurrence of lung cancer.
View Article and Find Full Text PDFReporting quality of animal research in journals that published the ARRIVE 1.0 or ARRIVE 2.0 guidelines: a cross-sectional analysis of 943 studies.
Cardiovasc Diagn Ther
December 2024
Editorial Office, AME Publishing Company, Hong Kong, China.
Background: The adherence to the Animals in Research: Reporting In Vivo Experiments (ARRIVE) guidelines across the journals that initially published the guidelines and if adherence has improved since the guidelines update, remains unknown. We aimed to quantify the level of adherence and analyze factors that might influence reporting quality among these journals.
Methods: This cross-sectional study retrospectively analyzed interventional animal experiments published in journals that released ARRIVE 1.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!